Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01880749 · ClinicalTrials.gov registry record · Early Phase 1
Exploring the Activity of RAD001 in Vestibular Schwannomas and Meningiomas
A Early Phase 1 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 5
- Enrollment target
NCT01880749 is a Early Phase 1 study that has completed, run by NYU Langone Health. The registered enrollment target is 5 participants.
The verdict
NCT01880749, a Early Phase 1 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
The primary objective is to estimate the proportions of vestibular schwannomas (VS) and meningiomas after 10 days of exposure to the study drug RAD001 at a dose of 10 mg daily, as determined by immunohistochemistry. This is a "phase 0" PK (pharmacokinetic) and PD (pharmacodynamic) study of RAD001 in patients with Neurofibromatosis Type 2-related and sporadic VS and meningiomas. Enrolled patients will take RAD001 prior to a scheduled VS or meningioma surgery, and blood and tissue samples will be obtained for further analysis.
Interventions
- DRUG RAD001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2013-06 |
| Est. Completion | 2019-12 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01880749
The ClinicalTrials.gov registry entry for NCT01880749 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RAD001 is the first listed.
NCT01880749 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01880749 about?
NCT01880749 is a clinical study titled "Exploring the Activity of RAD001 in Vestibular Schwannomas and Meningiomas". The primary objective is to estimate the proportions of vestibular schwannomas (VS) and meningiomas after 10 days of exposure to the study drug RAD001 at a dose of 10 mg daily, as determined by immunohistochemistry. This is a "phase 0" PK (pharmacokinetic) and PD (pharmacodynamic) study of RAD001 in...
What is the current status of trial NCT01880749?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 5 participants. The study started on 2013-06. Estimated completion is 2019-12.
What interventions are being tested in trial NCT01880749?
The interventions under investigation include: RAD001 (DRUG).
Who is sponsoring clinical trial NCT01880749?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.